|MARTA GAWŁOWSKA, RAFAŁ PAWLICZAK|
Rising asthma morbidity rates and often insufficient control of the disease achievable by means of currently available methods make it necessary to find new, safe and efficient therapeutic options. Long-acting beta-agonists have well-documented effect on the bronchoconstriction component of the asthma, but they lack the anti-inflammatory effect. Thus, they should not be used as the first line therapy in asthma treatment. The available data suggest that in patients whose asthma is not sufficiently controlled by means of anti-inflammatory drugs alone, the addition of LABA may bring good results. At the same time it has been stressed that the antiasthmatic therapy should be individualized and take into consideration all coexisting factors and individual patients’ response to the therapy. The aim of this review article is presentation of current results of the research on the mechanism of action of long-acting beta-agonists and the objective evaluation of their safety and efficacy.
keywords: astma, długo działające ?2-mimetyki, receptor ?2-adrenergiczny, synergizm, desensytyzacja, asthma, long-acting ?2-agonists, ?2-adrenergic receptor, synergy, desensitization
pages: from 142 to 154
|estimated time of download (365 kB)|